Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03094026 · ClinicalTrials.gov registry record · NA
Cognitive Training Intervention and Attitudes Towards Genetics
A NA study of Cognitive Impairment and Hematologic Neoplasms, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03094026: Recruiting NA study of Cognitive Impairment and Hematologic Neoplasms, sponsored by University of Alabama at Birmingham.
NCT03094026 is a NA study of Cognitive Impairment and Hematologic Neoplasms that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 60 participants, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03094026, a NA study of Cognitive Impairment and Hematologic Neoplasms, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
A pilot study to evaluate feasibility of enrollment of patients in an intervention to improve neurocognitive function in hematopoietic cell transplantation (HCT) survivors using the cognitive training Lumosity program. In addition, patients' interest in receiving information regarding genetic risk of cognitive impairment post-HCT will be measured.
Primary Outcome
Number of participants completing the 12 week intervention
Conditions Studied
Interventions
- BEHAVIORAL Lumosity
- BEHAVIORAL Lumosity (waitlist control)
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-08-21 |
| Est. Completion | 2026-07 |
| Phase | NA |
What NCT03094026 shows while recruiting
NCT03094026 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which Lumosity is the first listed.
NCT03094026 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT03094026 about?
NCT03094026 is a clinical study titled "Cognitive Training Intervention and Attitudes Towards Genetics". A pilot study to evaluate feasibility of enrollment of patients in an intervention to improve neurocognitive function in hematopoietic cell transplantation (HCT) survivors using the cognitive training Lumosity program. In addition, patients' interest in receiving information regarding genetic risk o...
What is the current status of trial NCT03094026?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2017-08-21. Estimated completion is 2026-07.
What conditions does trial NCT03094026 study?
This clinical trial studies the following conditions: Cognitive Impairment, Hematologic Neoplasms, Hematopoietic Cell Transplant.
What interventions are being tested in trial NCT03094026?
The interventions under investigation include: Lumosity (BEHAVIORAL), Lumosity (waitlist control) (BEHAVIORAL).
Who is sponsoring clinical trial NCT03094026?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03094026 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03094026's enrollment target sits among peer trials
60 64th of 105 higher than 39 of 105 other Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS
RECRUITING · NA
-
Mind Your Heart-II
RECRUITING · NA
-
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
RECRUITING · NA
-
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
RECRUITING · NA
-
Essential Fats For Enhancing Cognitive Thinking (EFFECT) Study
RECRUITING · NA
-
Amygdala Memory Enhancement
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI